Price Change to Note: Today Lantheus Holdings Inc Stock Rises

Price Change to Note: Today Lantheus Holdings Inc Stock Rises

The stock of Lantheus Holdings Inc (NASDAQ:LNTH) is a huge mover today! About 154,545 shares traded hands. Lantheus Holdings Inc (NASDAQ:LNTH) has risen 368.09% since April 5, 2016 and is uptrending. It has outperformed by 366.13% the S&P500.
The move comes after 8 months positive chart setup for the $347.34 million company. It was reported on Nov, 8 by Barchart.com. We have $13.11 PT which if reached, will make NASDAQ:LNTH worth $142.41M more.

Lantheus Holdings Inc (NASDAQ:LNTH) Ratings Coverage

Out of 5 analysts covering Lantheus Holdings (NASDAQ:LNTH), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Lantheus Holdings has been the topic of 9 analyst reports since August 31, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained it with “Outperform” rating and $6 target price in Wednesday, February 24 report. The stock of Lantheus Holdings Inc (NASDAQ:LNTH) earned “Neutral” rating by Robert W. Baird on Monday, August 31. The company was downgraded on Friday, December 11 by Credit Suisse. The firm earned “Neutral” rating on Friday, September 23 by Credit Suisse. The firm has “Buy” rating by Jefferies given on Monday, August 29. The rating was downgraded by Wells Fargo on Wednesday, September 30 to “Market Perform”.

According to Zacks Investment Research, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States.”

More recent Lantheus Holdings Inc (NASDAQ:LNTH) news were published by: Fool.com which released: “Why Lantheus Holdings Inc. Sold Lower Friday” on September 09, 2016. Also Businesswire.com published the news titled: “Lantheus Holdings, Inc. Reports 2016 Third Quarter Financial Results” on November 01, 2016. Businesswire.com‘s news article titled: “Lantheus Holdings, Inc. Announces Public Offering of 5200000 Shares of Common …” with publication date: September 08, 2016 was also an interesting one.

LNTH Company Profile

Lantheus Holdings, Inc., incorporated on November 30, 2007, develops, makes and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment